Cancer of unknown primary presents a unique clinical conundrum wherein metastatic tumors are detected, but the primary tumor remains elusive despite exhaustive diagnostic efforts. This obscurity complicates treatment strategies, as common oncologic protocols often rely on primary tumor biology to select targeted therapies. Conventional treatment modalities for CUP have been largely empirical, with chemotherapy regimens providing modest benefits at best. The urgent need for tailored therapies targeting the tumor microenvironment and immune evasion mechanisms has motivated the exploration of immune checkpoint inhibitors and anti-angiogenic agents in this context.

The rationale behind co-administering anti-PD-1 inhibitors with nab-paclitaxel and bevacizumab stems from the intricate interplay between tumor immunogenicity, angiogenesis, and chemotherapeutic sensitization. PD-1, or programmed death-1 receptor, is an immune checkpoint molecule expressed on T cells that downregulates immune responses when engaged by its ligands PD-L1 and PD-L2, commonly overexpressed on tumor cells. Blocking this pathway with anti-PD-1 antibodies reactivates T cell-mediated anti-tumor immunity. However, monotherapy with checkpoint inhibitors in CUP patients has yielded heterogeneous responses, necessitating combination strategies.

Nab-paclitaxel’s unique formulation leverages albumin’s natural transport pathways to enhance intratumoral drug delivery and minimize systemic toxicity, thereby potentiating chemotherapeutic effects. Beyond cytotoxicity, chemotherapy can induce immunogenic cell death, releasing tumor antigens and promoting dendritic cell activation, which synergizes with checkpoint inhibition. Meanwhile, bevacizumab targets vascular endothelial growth factor (VEGF), a key driver of tumor angiogenesis that also exerts immunosuppressive effects by recruiting regulatory T cells and myeloid-derived suppressor cells within the tumor niche. By normalizing tumor vasculature and mitigating VEGF-mediated immune evasion, bevacizumab complements the immune-activating properties of anti-PD-1 therapy.

The Fudan CUP-002 trial enrolled patients diagnosed with CUP who had exhausted first-line therapies or were intolerant to standard treatments. Researchers meticulously tailored dosing schedules to optimize efficacy while monitoring for adverse effects inherent in combined immunochemotherapy protocols. The trial’s endpoints included objective response rate, progression-free survival, overall survival, and safety assessments, providing a robust evaluation of the regimen’s clinical value.

Results from the study were compelling. A significant proportion of patients attained durable partial or complete responses, with enhanced progression-free survival compared to historical controls treated with conventional chemotherapy alone. The observed responses were particularly notable given the heterogeneity of CUP tumors and the absence of confirmed primary tumor sites, underscoring the regimen’s broad therapeutic potential. Importantly, the safety profile was manageable, with adverse events consistent with the known toxicities of the individual agents, and no unexpected synergistic toxicities emerged.

Mechanistic insights gleaned from biopsy samples and peripheral blood analyses revealed heightened infiltration of cytotoxic CD8+ T cells within tumor microenvironments post-treatment, accompanied by decreases in immunosuppressive cell populations. These immunologic shifts affirm the hypothesized synergy between anti-PD-1-mediated immune reactivation and bevacizumab-driven vascular normalization, augmented further by chemotherapy-induced antigen release. The integrative approach appears to recalibrate the tumor milieu from immunologically “cold” to “hot,” facilitating effective immune surveillance and tumor eradication.

Moreover, molecular profiling of responders indicated certain biomarkers predictive of treatment efficacy, including elevated PD-L1 expression and specific gene signatures associated with angiogenic pathways and immune cell infiltration. These findings pave the way for precision medicine approaches in CUP, enabling clinicians to identify patients most likely to benefit from this combination therapy and sparing others from ineffective and potentially toxic treatments.

The novelty and impact of this trial extend beyond CUP, offering a paradigm for tackling other malignancies characterized by therapeutic resistance and diagnostic uncertainty. By harnessing the complementary mechanisms of immune checkpoint blockade, chemotherapy enhancement, and anti-angiogenesis, this triad exemplifies the future of multidimensional cancer treatment strategies. It challenges researchers to continue unraveling tumor biology intricacies and develop increasingly sophisticated therapeutic combinations.

As the oncology community digests these findings, questions remain around long-term outcomes, resistance mechanisms that may eventually emerge, and the feasibility of integrating this regimen into standard practice given cost and resource considerations. Ongoing phase III trials and real-world evidence will be pivotal in validating efficacy and refining patient selection criteria. Additionally, expanding biomarker discovery efforts will enhance prognostic accuracy and therapeutic precision.

The psychological and clinical burden faced by patients with cancer of unknown primary cannot be overstated. This trial breathes new optimism into an area previously marked by therapeutic nihilism. The observed durable responses and improved survival metrics represent a clarion call to revisit treatment algorithms and prioritize immune-angiogenesis-chemotherapy synergistic regimens in refractory or diagnostically ambiguous cancers.

In conclusion, the Fudan CUP-002 phase II trial heralds a transformative advancement in oncology by demonstrating that a combination of anti-PD-1 immunotherapy, nab-paclitaxel chemotherapy, and bevacizumab anti-angiogenic therapy can deliver significant clinical benefits to patients with a notoriously difficult-to-treat cancer subtype. This tripartite strategy leverages complementary biological mechanisms to convert immunologically inert tumors into targets susceptible to immune-mediated eradication, thereby rewriting the therapeutic playbook for cancer of unknown primary.

Continued exploration of this regimen in larger, randomized trials alongside mechanistic studies will illuminate the path toward optimized, personalized cancer care. As we stand at this frontier of cancer therapy innovation, the integration of immune modulation, vascular normalization, and chemotherapeutic precision offers a beacon of hope for patients and clinicians confronting the complexities of cancer’s unknown origins.

Subject of Research: Cancer of unknown primary (CUP) treatment with combined anti-PD-1 immunotherapy, nab-paclitaxel chemotherapy, and bevacizumab anti-angiogenic therapy.

Article Title: Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial.

Article References:

Zhang, X., Zhao, T., Xu, M. et al. Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial.
Nat Commun (2026). https://doi.org/10.1038/s41467-026-72745-6

Image Credits: AI Generated

Malignant pleural effusion is essentially the pathological accumulation of fluid in the pleural space caused by cancer metastasis, most commonly originating from lung carcinoma. The condition frequently results in respiratory distress and significantly contributes to morbidity and mortality in affected individuals. Current therapeutic interventions often revolve around symptomatic relief through drainage and systemic chemotherapy, but these approaches fail to effectively control tumor progression or fluid accumulation within the pleural cavity. Hence, this research addresses a critical gap by evaluating targeted intrapleural therapy designed to simultaneously combat tumor proliferation and angiogenesis.

The study utilized a well-established murine model of malignant pleural effusion induced by intrapleural injection of Lewis Lung Carcinoma (LLC) cells. Over 300 mice were subjected to LLC cell implantation to recapitulate the human disease phenotype, including tumor implantation in the pleural lining and pleural fluid accumulation. This model is instrumental for preclinical evaluation of new intrapleural therapeutic agents due to its reproducibility and clinical relevance to human lung cancer-associated MPE.

Upon establishing the malignant effusion, the mice were stratified into five distinct groups receiving intrapleural treatments. These groups included administration of conventional Paclitaxel, nanoparticle albumin-bound Paclitaxel (nab-Paclitaxel), anti-VEGF antibody therapy, a combination of nab-Paclitaxel with anti-VEGF, and a control group treated with saline. The study meticulously monitored a subset of animals longitudinally, analyzing weight changes, mobility, survival outcomes, as well as biochemical and histological parameters within the pleural effusion and tissue microenvironment.

One key advantage of nab-Paclitaxel, as leveraged in this study, lies in its nanoparticle formulation, which enhances drug delivery and tumor penetration while simultaneously reducing systemic toxicity. The albumin-bound nanoparticles facilitate efficient transcytosis via endothelial cells, promoting drug accumulation within the pleural tumor nodules. Combining this enhanced cytotoxic drug delivery system with anti-angiogenic therapy theoretically halts tumor vascularization – a critical mechanism driving tumor sustenance and pleural fluid formation.

The results revealed a stark contrast between the treatment groups when analyzing survival, tumor burden, and pleural fluid volume. Notably, the group receiving the combined nab-Paclitaxel and anti-VEGF treatment exhibited the longest median survival times, significantly outperforming both monotherapy and control groups. The combination therapy effectively suppressed tumor implantation scores within the pleura and markedly curtailed the accumulation of pleural fluid, demonstrating superiority over standard Paclitaxel treatment modalities.

The biochemical analysis of the pleural fluid reflected underlying inflammatory and tumor microenvironment dynamics. Markers such as lactate dehydrogenase (LDH), interleukin-6 (IL-6), VEGF, and tumor necrosis factor-alpha (TNF-α) were quantified and correlated with treatment efficacy. The combination therapy group consistently showed reductions in these pro-inflammatory and pro-angiogenic mediators, suggesting a robust modulation of the pleural tumor microenvironment that impedes both tumor survival and inflammatory-driven fluid exudation.

Histological examinations further substantiated the therapeutic benefit of the intrapleural combination. Pleural tissues from treated animals showed decreased neovascularization, less dense tumor nodules, and reduced signs of pleural inflammation and fibrosis in the nab-Paclitaxel plus anti-VEGF group. This histopathological evidence aligns with the clinical metrics of reduced effusion volume and enhanced animal mobility, underscoring the potential translational relevance of this treatment approach.

The mechanistic rationale for integrating VEGF inhibition with chemotherapy aligns with the established role of VEGF as a central mediator of angiogenesis and vascular permeability, both of which are driving forces behind malignant effusions. Blocking VEGF signaling disrupts new blood vessel formation essential for tumor growth and reduces pleural fluid leakage by stabilizing vascular barriers. Meanwhile, nab-Paclitaxel delivers potent cytotoxic effects directly to neoplastic cells, facilitating combined suppression of the tumor niche.

This investigation also sheds light on potential clinical implications for human therapy. Current management of malignant pleural effusion is limited and often palliative, underscoring the urgent need for innovative localized treatments that not only reduce symptoms but also modify disease trajectory. The use of localized intrapleural delivery systems can minimize systemic side effects commonly observed with conventional chemotherapy, providing a more targeted and tolerable option for patients with advanced lung cancer and effusions.

Moreover, the success of nanoparticle-based drug delivery in this study could fuel broader adoption of nanomedicine in oncological pleural diseases. By tailoring the physicochemical properties of therapeutic agents, researchers can optimize drug retention time and penetration depth within pleural tumors, potentially revolutionizing treatment paradigms for diverse thoracic malignancies.

The study also highlights vital parameters for future research, including dosing schedules, long-term safety, and potential combinational regimens with immunotherapies. Evaluating how nab-Paclitaxel and anti-VEGF interface with the host immune response in the pleural space may unearth synergistic pathways that could amplify anticancer efficacy.

Furthermore, this report emphasizes the importance of rigorous murine models that closely mimic human pathology in preclinical drug development. The Lewis Lung Carcinoma intrapleural model successfully recapitulated key aspects of human MPE, validating its use as a platform for testing novel therapeutics and understanding molecular underpinnings of pleural metastasis.

While the findings are compelling, translation to clinical practice requires human trials to assess safety, optimal dosing, and effectiveness in diverse patient populations. Given the minimal invasiveness of intrapleural therapy, patient compliance and quality of life considerations are likely to be favorable compared to systemic cytotoxic regimens.

In conclusion, the research undertaken by Silva et al. represents a significant leap forward in malignant pleural effusion therapy. By combining intrapleural nanoparticle-enabled chemotherapy with targeted antiangiogenic treatment, the approach not only diminishes tumor burden but also improves survival outcomes in a robust experimental model. This dual modality strategy holds promise to redefine therapeutic landscapes and bring new hope for patients suffering from this devastating oncological condition.

Subject of Research: Malignant pleural effusion treatment using intrapleural nanoparticle albumin-bound paclitaxel combined with anti-vascular endothelial growth factor therapy in murine models.

Article Title: Effect of intrapleural anti-Vascular Endothelial Growth Factor (VEGF) associated with nab paclitaxel in a murine model of malignant pleural effusion.

Article References:
Silva, C.S.R., Teixeira, L.R., Pereira, K.R. et al. Effect of intrapleural anti-Vascular Endothelial Growth Factor (VEGF) associated with nab paclitaxel in a murine model of malignant pleural effusion. BMC Cancer 25, 1261 (2025). https://doi.org/10.1186/s12885-025-14622-x

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14622-x